B. Riley upgraded Anterix (ATEX) from Neutral to Buy and increased its price target to $103 from $86. This positive analyst action follows the company's recent fiscal Q2 2027 earnings report, suggesting a favorable re-evaluation of its prospects.
Investment firm B. Riley upgraded Anterix (ATEX) from Neutral to Buy and raised its price target from $86 to $103. This positive revision by a notable investment firm typically signals increased confidence in the company's future performance, likely driven by the recent fiscal Q2 2027 earnings report. For traders, this could lead to short-term positive price momentum for ATEX as the market reacts to the upgraded outlook. The long-term implications depend on whether Anterix can meet or exceed the expectations implied by the new price target. A key opportunity for traders is to capitalize on potential upward movement, while the risk lies in whether the market has already priced in this upgrade or if future company performance fails to justify the new rating.